N-Acetylglutamate synthase deficiency

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD medical weight loss and sleep centers

---

WikiMD Resources for N-Acetylglutamate synthase deficiency
Articles
Most recent articles on N-Acetylglutamate synthase deficiency Most cited articles on N-Acetylglutamate synthase deficiency Review articles on N-Acetylglutamate synthase deficiency Articles on N-Acetylglutamate synthase deficiency in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on N-Acetylglutamate synthase deficiency Images of N-Acetylglutamate synthase deficiency Photos of N-Acetylglutamate synthase deficiency Podcasts & MP3s on N-Acetylglutamate synthase deficiency Videos on N-Acetylglutamate synthase deficiency
Evidence Based Medicine
Cochrane Collaboration on N-Acetylglutamate synthase deficiency Bandolier on N-Acetylglutamate synthase deficiency TRIP on N-Acetylglutamate synthase deficiency
Clinical Trials
Ongoing Trials on N-Acetylglutamate synthase deficiency at Clinical Trials.gov Trial results on N-Acetylglutamate synthase deficiency Clinical Trials on N-Acetylglutamate synthase deficiency at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on N-Acetylglutamate synthase deficiency NICE Guidance on N-Acetylglutamate synthase deficiency NHS PRODIGY Guidance FDA on N-Acetylglutamate synthase deficiency CDC on N-Acetylglutamate synthase deficiency
Books
Books on N-Acetylglutamate synthase deficiency
News
N-Acetylglutamate synthase deficiency in the news Be alerted to news on N-Acetylglutamate synthase deficiency News trends on N-Acetylglutamate synthase deficiency
Commentary
Blogs on N-Acetylglutamate synthase deficiency
Definitions
Definitions of N-Acetylglutamate synthase deficiency
Patient Resources / Community
Patient resources on N-Acetylglutamate synthase deficiency Discussion groups on N-Acetylglutamate synthase deficiency Patient Handouts on N-Acetylglutamate synthase deficiency Directions to Hospitals Treating N-Acetylglutamate synthase deficiency Risk calculators and risk factors for N-Acetylglutamate synthase deficiency
Healthcare Provider Resources
Symptoms of N-Acetylglutamate synthase deficiency Causes & Risk Factors for N-Acetylglutamate synthase deficiency Diagnostic studies for N-Acetylglutamate synthase deficiency Treatment of N-Acetylglutamate synthase deficiency
Continuing Medical Education (CME)
CME Programs on N-Acetylglutamate synthase deficiency
International / other languages
synthase deficiency en Espanol synthase deficiency en Francais
Business
N-Acetylglutamate synthase deficiency in the Marketplace Patents on N-Acetylglutamate synthase deficiency
Experimental / Informatics
List of terms related to N-Acetylglutamate synthase deficiency

N-Acetylglutamate synthase deficiency is an autosomal recessive urea cycle disorder.

Signs and symptoms

The symptoms are visible within the first week of life and if not detected and diagnosed correctly immediately consequences are fatal.

Genetics

N-Acetylglutamate synthase deficiency has an autosomal recessive pattern of inheritance.

The figure shows human chromosome 17q and the coding region that encodes the NAGS enzyme. It has seven exons and six introns. The exons are shown as red squares.

The chromosome found to be carrying the gene encoding for N-Acetyl Glutamate synthetase is chromosome 17q (q stands for longer arm of the chromosome) in humans and chromosome 11 in mice. In both organisms, the chromosome consists of seven exons and six introns and non-coding sequence.

The cause for this disorder is a single base deletion that led to frameshift mutation, and thus the error in gene's coding for this specific enzyme.

Mechanism

Carbamoyl phosphate synthase I is an enzyme found in mitochondrial matrix and it catalyzes the very first reaction of the Urea cycle, in which carbamoyl phosphate is produced.

Carbamoyl Phosphate Synthase 1, abbreviated as CPS1, is activated by its natural activator N-Acetyl glutamate, which in turn is synthesized from acetyl-CoA and glutamic acid in the reaction catalyzed by N-Acetyl glutamate synthase, commonly called NAGS. N-Acetyl Glutamate is required for the Urea cycle to take place.

Deficiency in N-Acetylglutamate synthase or a genetic mutation in the gene coding for the enzyme, will lead to urea cycle failure in which ammonia is not converted to urea, but rather accumulated in blood leading to the condition called Type I Hyperammonemia. This is a severe neonatal disorder with fatal consequences, if not detected immediately upon birth.

Treatment

Although there is currently no cure, treatment includes injections of structurally similar compound, Carglumic acid, an analogue of N-Acetyl Glutamate. This analogue likewise activates CPS1. This treatment mitigates the intensity of the disorder.

If symptoms are detected early enough and the patient is injected with this compound, levels of severe mental retardation can be slightly lessened, but brain damage is irreversible.

Also: hemodialysis for emergent hyperammonemic crisis, Na benzoate, Na phenylacetate, Na phenylbutyrate, low-protein diet supplemented with essential amino acid mixture and arginine, citrulline, experimental attempts at gene therapy, liver transplantation (which is curative), and also N-carbamylglutamate supplementation.

Early symptoms include lethargy, vomiting, and deep coma.

See also

• Hyperammonemia
• Urea cycle

External links

Classification	OMIM: 237310 DiseasesDB: 29823
External resources	eMedicine: ped/10

• GeneReviews/NCBI/NIH/UW entry on Urea Cycle Disorders Overview
• The National Urea Cycle Disorders Foundation